SCHEMBL1363726

SCHEMBL1363726

CCN1CCN(c2cccc(Nc3nccc(-c4c(-c5cccc(NC(=O)c6c(F)cccc6F)c5)nc5sccn45)n3)c2)C(=O)C1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 14/20 0.79
EGFR P00533 14/20 0.79
ERBB2 P04626 14/20 0.79
MAP4K4 O95819 6/20 0.79
LCK P06239 6/20 0.79
KDR P35968 6/20 0.79
RET P07949 5/20 0.79
MAP4K2 Q12851 5/20 0.79
STK3 Q13188 5/20 0.79
TAOK1 Q7L7X3 5/20 0.79
MAP4K5 Q9Y4K4 5/20 0.79
PRKD3 O94806 4/20 0.79
FYN P06241 4/20 0.79
AURKB Q96GD4 4/20 0.79
CSF1R P07333 4/20 0.79
AURKA O14965 3/20 0.79
INSR P06213 3/20 0.79
LYN P07948 3/20 0.79
FGFR1 P11362 3/20 0.79
SRC P12931 3/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1363691 0.95 EGFR (0.83) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1362385 0.91 EGFR (0.70) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1364604 0.91 IGF1R (0.90) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1363449 0.89 EGFR (0.64) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1363536 0.89 EGFR (0.71) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1363195 0.89 EGFR (1.00) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1361783 0.88 IGF1R (0.81) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1363318 0.87 EGFR (0.83) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1362775 0.87 EGFR (1.00) IGF1REGFRERBB2MAP4K4LCK
SCHEMBL1364428 0.86 EGFR (0.72) IGF1REGFRERBB2MAP4K4LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US claimed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885EGFR 591/4885ERBB2 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.